Glenmark Pharmaceuticals Ltd has found a big pharma licensee in Sanofi-aventis for its chronic pain agents that are under development. Simultaneously, its US subsidiary has entered into an agreement with Par Pharmaceutical to market the generic cholesterol drug ezetimibe in the US.